Collectively, these findings indicate that combined inhibition of GPR171 and EGFR may be a promising strategy for lung cancer treatment, reflecting the fact that GPR171 induces tumorigenesis in an EGFR-independent manner. Here, GPR171 is linked to lung cancer.